Page last updated: 2024-11-08

vasopressin, deamino-homo-arg-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

vasopressin, deamino-homo-Arg-: RN given refers to (L-Lysine)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID171190
MeSH IDM0084209

Synonyms (8)

Synonym
deamino-homoarginine vasopressin
1-deamino-8-homoarginine vasopressin
52697-47-9
deamino-homo-arg-vasopressin
vasopressin, deamino-homoarginine-
vasopressin, 1-(3-mercaptopropanoic acid)-8-(n(6)-(aminoiminomethyl)-l-lysine)-
vasopressin, deamino-homo-arg-
1-deamino-8-d-homoarginine-vasopressin

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" After intravenous administration, the half-life of elimination (t1/2) of dDAVP was 78 +/- 10 minutes."( Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers.
Fjellestad-Paulsen, A; Höglund, P; Lundin, S; Paulsen, O, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Plasma DDAVP concentration/time curves conformed closely with zero-order kinetics, which suggests that the bioavailability approached 100%, corresponding to that for direct intravenous infusion."( Administration of antidiuretic peptide (DDAVP) by way of suction de-epithelialised skin.
Lundin, S; Svedman, C; Svedman, P, 1991
)
0.28
"The bioavailability of dDAVP seems lower than previously reported after intranasal and oral administration."( Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers.
Fjellestad-Paulsen, A; Höglund, P; Lundin, S; Paulsen, O, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (66.67)18.7374
1990's4 (26.67)18.2507
2000's0 (0.00)29.6817
2010's1 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (20.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (73.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]